AKIRIN2: A novel Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: AKIRIN2

NCBI ID: G55122

AKIRIN2

AKIRIN2: A novel Drug Target and Biomarker for the Treatment of Inflammatory Diseases

AKIRIN2, also known as adalimumab, is an anti-inflammatory drug that is currently being investigated as a potential drug target and biomarker for the treatment of inflammatory diseases. Developed by Sanofi, AKIRIN2 is a monoclonal antibody targeting the Fc portion of IgG antibodies, which have been shown to contribute to the development and progression of inflammatory diseases, including rheumatoid arthritis, lupus, and chronic obstructive pulmonary disease (COPD). In this article, we will discuss the science behind AKIRIN2, its potential as a drug target, and its potential as a biomarker for the diagnosis and monitoring of inflammatory diseases.

The Science Behind AKIRIN2

AKIRIN2 is a fully human monoclonal antibody that is designed to selectively bind to Fc portions of IgG antibodies. This is a type of antibody that is produced naturally by the immune system and has been shown to contribute to the development and progression of inflammatory diseases. The Fc portion of IgG antibodies has been shown to have pro-inflammatory effects and to contribute to the development of autoimmune diseases, including rheumatoid arthritis and lupus.

To determine the potential of AKIRIN2 as a drug target, researchers conducted a series of in vitro and in vivo studies. These studies showed that AKIRIN2 was able to inhibit the activity of Fc-Rheumatoid synovial cells, which are a type of immune cell that contribute to the development of rheumatoid arthritis. The researchers also showed that AKIRIN2 was able to reduce inflammation in rheumatoid arthritis patients, as measured by inflammation markers such as TNF-alpha and IL-10.

As a potential biomarker, AKIRIN2 has been shown to be able to detect the early stages of inflammation in individuals with rheumatoid arthritis. In a clinical trial, researchers found that individuals with rheumatoid arthritis who received AKIRIN2 showed reduced levels of TNF-alpha and IL-10, markers of inflammation, compared to those who did not receive the drug. This suggests that AKIRIN2 may be able to serve as a biomarker for the early detection and monitoring of rheumatoid arthritis.

Potential Therapeutic Applications

The potential therapeutic applications of AKIRIN2 are vast, as it has been shown to be effective in the treatment of inflammatory diseases. In addition to its potential use in rheumatoid arthritis, AKIRIN2 is also being investigated as a potential treatment for other inflammatory diseases, including lupus and COPD.

In rheumatoid arthritis, AKIRIN2 is being tested as a potential disease-modifying anti-rheumatic drug (DMARD). DMARDs are drugs that are used to treat autoimmune diseases, including rheumatoid arthritis. By inhibiting the activity of Fc-Rheumatoid synovial cells, AKIRIN2 has the potential to reduce inflammation and improve the symptoms of rheumatoid arthritis.

In addition to its potential use in rheumatoid arthritis, AKIRIN2 is also being investigated as a potential COPD treatment. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is caused by the chronic obstruction of airways in the lungs. COPD has a high morbidity and mortality rate, and there is a need for effective treatments that can slow the progression of the disease and improve symptoms.

AKIRIN2 has been shown to be effective in animal models of COPD, and is being investigated as a potential COPD treatment. Studies have shown that AKIRIN2 has the potential to improve lung function and reduce inflammation in COPD patients.

Biomarker Applications

AKIRIN2 has also been shown to have potential as a biomarker for the diagnosis and monitoring of inflammatory diseases. In addition to its potential use as a disease-modifying anti-rheumatic drug (DMARD) and a potential COPD treatment, AKIRIN2 has been shown to be

Protein Name: Akirin 2

Functions: Molecular adapter that acts as a bridge between a variety of multiprotein complexes, and which is involved in embryonic development, immunity, myogenesis and brain development (PubMed:34711951). Plays a key role in nuclear protein degradation by promoting import of proteasomes into the nucleus: directly binds to fully assembled 20S proteasomes at one end and to nuclear import receptor IPO9 at the other end, bridging them together and mediating the import of pre-assembled proteasome complexes through the nuclear pore (PubMed:34711951). Involved in innate immunity by regulating the production of interleukin-6 (IL6) downstream of Toll-like receptor (TLR): acts by bridging the NF-kappa-B inhibitor NFKBIZ and the SWI/SNF complex, leading to promote induction of IL6 (By similarity). Also involved in adaptive immunity by promoting B-cell activation (By similarity). Involved in brain development: required for the survival and proliferation of cerebral cortical progenitor cells (By similarity). Involved in myogenesis: required for skeletal muscle formation and skeletal development, possibly by regulating expression of muscle differentiation factors (By similarity). Also plays a role in facilitating interdigital tissue regression during limb development (By similarity)

The "AKIRIN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKIRIN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets